150 related articles for article (PubMed ID: 16652053)
1. Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999-2004: a longitudinal analysis.
Carter RJ; Wiener J; Abrams EJ; Farley J; Nesheim S; Palumbo P; Bulterys M;
J Acquir Immune Defic Syndr; 2006 Apr; 41(4):453-60. PubMed ID: 16652053
[TBL] [Abstract][Full Text] [Related]
2. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
3. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study.
Tsiodras S; Mantzoros C; Hammer S; Samore M
Arch Intern Med; 2000 Jul; 160(13):2050-6. PubMed ID: 10888979
[TBL] [Abstract][Full Text] [Related]
4. Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study.
Patroni A; Torti C; Tomasoni L; Quiros Roldan E; Bertelli D; Puoti M; Cadeo GP; Sleiman I; Tinelli C; Carosi G; Castelli F
HIV Clin Trials; 2002; 3(6):451-61. PubMed ID: 12501128
[TBL] [Abstract][Full Text] [Related]
5. Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children.
Tassiopoulos K; Williams PL; Seage GR; Crain M; Oleske J; Farley J;
J Acquir Immune Defic Syndr; 2008 Apr; 47(5):607-14. PubMed ID: 18209684
[TBL] [Abstract][Full Text] [Related]
6. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.
Lainka E; Oezbek S; Falck M; Ndagijimana J; Niehues T
Pediatrics; 2002 Nov; 110(5):e56. PubMed ID: 12415062
[TBL] [Abstract][Full Text] [Related]
7. Dyslipidemia in a cohort of HIV-infected Latin American children receiving highly active antiretroviral therapy.
Brewinski M; Megazzini K; Hance LF; Cruz MC; Pavia-Ruz N; Della Negra M; Ferreira FG; Marques H; Hazra R;
J Trop Pediatr; 2011 Oct; 57(5):324-32. PubMed ID: 20889625
[TBL] [Abstract][Full Text] [Related]
8. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
Périard D; Telenti A; Sudre P; Cheseaux JJ; Halfon P; Reymond MJ; Marcovina SM; Glauser MP; Nicod P; Darioli R; Mooser V
Circulation; 1999 Aug; 100(7):700-5. PubMed ID: 10449690
[TBL] [Abstract][Full Text] [Related]
9. Hypertriglyceridemia and hypercholesterolemia in human immunodeficiency virus-1-infected children treated with protease inhibitors.
Solórzano Santos F; Gochicoa Rangel LG; Palacios Saucedo G; Vázquez Rosales G; Miranda Novales MG
Arch Med Res; 2006 Jan; 37(1):129-32. PubMed ID: 16314198
[TBL] [Abstract][Full Text] [Related]
10. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens.
Taylor P; Worrell C; Steinberg SM; Hazra R; Jankelevich S; Wood LV; Zwerski S; Yarchoan R; Zeichner S
Pediatrics; 2004 Aug; 114(2):e235-42. PubMed ID: 15286262
[TBL] [Abstract][Full Text] [Related]
11. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.
Jao J; Yu W; Patel K; Miller TL; Karalius B; Geffner ME; DiMeglio LA; Mirza A; Chen JS; Silio M; McFarland EJ; Van Dyke RB; Jacobson D;
HIV Med; 2018 Mar; 19(3):175-183. PubMed ID: 29159965
[TBL] [Abstract][Full Text] [Related]
12. Lipodystrophy in HIV-infected pediatric patients receiving protease inhibitors.
Temple ME; Koranyi KI; Nahata MC
Ann Pharmacother; 2003 Sep; 37(9):1214-8. PubMed ID: 12921501
[TBL] [Abstract][Full Text] [Related]
13. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Aurpibul L; Puthanakit T; Lee B; Mangklabruks A; Sirisanthana T; Sirisanthana V
Antivir Ther; 2007; 12(8):1247-54. PubMed ID: 18240864
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.
Ruiz L; Negredo E; Domingo P; Paredes R; Francia E; Balagué M; Gel S; Bonjoch A; Fumaz CR; Johnston S; Romeu J; Lange J; Clotet B;
J Acquir Immune Defic Syndr; 2001 Jul; 27(3):229-36. PubMed ID: 11464141
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
[TBL] [Abstract][Full Text] [Related]
16. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load.
Gil P; de Górgolas M; Estrada V; Arranz A; Rivas P; Yera C; García R; Granizo JJ; Fernández-Guerrero M
Clin Infect Dis; 2004 Oct; 39(7):1024-9. PubMed ID: 15472856
[TBL] [Abstract][Full Text] [Related]
18. Lipid levels in the second year of life among HIV-infected and HIV-exposed uninfected Latin American children.
Hazra R; Cohen RA; Gonin R; Monteiro JP; Hofer CB; Negra MD; Ruz NP;
AIDS; 2012 Jan; 26(2):235-40. PubMed ID: 22008654
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4-19 years old) in Pediatric AIDS Clinical Trials Group 219C.
Farley J; Gona P; Crain M; Cervia J; Oleske J; Seage G; Lindsey J;
J Acquir Immune Defic Syndr; 2005 Apr; 38(4):480-7. PubMed ID: 15764965
[TBL] [Abstract][Full Text] [Related]
20. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
Manfredi R; Chiodo F
J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
